These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15648222)

  • 1. Managing clinical trials--frustration or bliss?
    Willenberg KM
    J Oncol Manag; 2004; 13(6):24-6. PubMed ID: 15648222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmaceutical industry's responsibility for protecting human subjects of clinical trials in developing nations.
    Kelleher F
    Columbia J Law Soc Probl; 2004; 38(1):67-106. PubMed ID: 16755695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Priority setting and the ethics of resource allocation within VA healthcare facilities: results of a survey.
    Foglia MB; Pearlman RA; Bottrell MM; Altemose JA; Fox E
    Organ Ethic; 2008; 4(2):83-96. PubMed ID: 18839751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Unnecessary delays in ethical approval of multicentre clinical trials].
    Evers JL
    Ned Tijdschr Geneeskd; 2008 Sep; 152(38):2062-4. PubMed ID: 18837181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits to research subjects in international trials: do they reduce exploitation or increase undue inducement?
    Ballantyne A
    Dev World Bioeth; 2008 Dec; 8(3):178-91. PubMed ID: 19046255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying justice in clinical trials for diverse populations.
    Tilburt J; Ford JG; Howerton MW; Gary TL; Lai GY; Bolen S; Baffi C; Wilson RF; Tanpitukpongse TP; Powe NR; Bass EB; Sugarman J
    Clin Trials; 2007; 4(3):264-9. PubMed ID: 17715253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare reimbursement for clinical trial services: understanding Medicare coverage in establishing a clinical trial budget.
    Barnes M; Korn J
    J Health Law; 2005; 38(4):609-31. PubMed ID: 16673632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and challenges in clinical ethics consultations: the experiences of nine clinical ethics committees.
    Pedersen R; Akre V; Førde R
    Bioethics; 2009 Oct; 23(8):460-9. PubMed ID: 18549426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
    Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
    Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional review boards (IRBs) and working with adverse event reports.
    Maloney DM
    Hum Res Rep; 2005 Dec; 20(12):1-3. PubMed ID: 16607708
    [No Abstract]   [Full Text] [Related]  

  • 15. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.
    Dilts DM; Sandler AB
    J Clin Oncol; 2006 Oct; 24(28):4545-52. PubMed ID: 17008693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case study: research subject says institutional review board (IRB) was no help.
    Maloney DM
    Hum Res Rep; 2006 Jan; 21(1):7. PubMed ID: 16789306
    [No Abstract]   [Full Text] [Related]  

  • 17. The tip of the iceberg: financial liability analysis and clinical trials.
    Baio KT; Takamoto R
    Healthc Financ Manage; 2006 Jun; 60(6):102-4, 106, 108. PubMed ID: 16773995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Institutional review boards must conduct safety review.
    Maloney DM
    Hum Res Rep; 2005 Feb; 20(2):3. PubMed ID: 15839005
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug development: assessment of pharmacogenetic studies by Spanish research ethics committees.
    Dal-Ré R; Luque I; Torres R; Lahuerta J
    Pharmacogenomics J; 2009 Apr; 9(2):86-9. PubMed ID: 19079365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Registering clinical trials in India: a scientific and ethical imperative.
    Tharyan P; Ghersi D
    Natl Med J India; 2008; 21(1):31-4. PubMed ID: 18472701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.